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Abstract 
Objective: Coronary artery bypass grafting (CABG) using bilateral internal 
mammary arteries (BIMA) may improve survival over CABG using single internal 
mammary arteries (SIMA), but may be surgically more complex (and therefore 
costly) and associated with impaired sternal wound healing. We report, for the first 
time, a detailed comparison of health care resource use and costs over 12 months, 
as part of the Arterial Revascularisation (ART) Trial. 
Methods: 3102 patients in 28 hospitals in 7 countries were randomised to CABG 
surgery using BIMA (n=1548) or SIMA (n=1554). Detailed resource use data were 
collected covering surgery, the initial hospital episode, and for 12 months post 
randomisation. Using UK unit costs, total costs were calculated and compared 
between trial arms and for sub-groups.  
Results: Patients randomised to BIMA spent 20 minutes longer in theatre (95% CI 
15 to 25, p<0.001), and also required more treatment for sternal wound problems. 
Mean (SD) total costs per patient at 12 months were £13,839 (£10,534) for BIMA 
and £12,717 (£9,719) for SIMA (mean cost difference £1122, 95% CI £407 to 
£1,838, p=0.002). No tests for interaction between subgroups and treatment 
allocation were significant. 
Conclusions: At 12 months from randomisation, mean costs were approximately 
9% higher in BIMA than SIMA patients, primarily due to longer time in theatre and in-
hospital stay, and slightly higher costs related to sternal wound problems during 
follow-up. Follow-up to the primary trial endpoint of 10 years will reveal whether 
longer-term differences emerge in graft patency or in overall survival.   
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KEY MESSAGES 
What is already known about this subject? 
Coronary artery bypass grafting is a safe, effective and high volume procedure, but 
patient outcomes might be further improved by using bilateral internal mammary 
arteries (BIMA), which may offer better long-term graft patency and survival. No 
randomised comparison of the costs of these procedures has been published.  
What does this study add? 
Using data from the Arterial Revascularisation Trial, we show that at 12 months from 
randomisation costs were approximately 9% higher in BIMA than SIMA patients, 
mainly due to longer time in theatre and in-hospital stay, and slightly higher costs 
related to sternal wound problems during follow-up. These cost differences were 
larger in some sub-groups, such as diabetes vs. non-diabetes. 
How might this impact on clinical practice? 
Our findings will be valuable to clinicians and health policy makers considering the 
potential cost implications of moving from SIMA to BIMA, for all eligible patients or 
particular sub-groups. Researchers will require these cost estimates to assess the 
long-term cost-effectiveness of BIMA.     
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INTRODUCTION 
During coronary artery bypass grafting (CABG) most patients receive three bypass 
grafts, one to each of the major coronary arteries.  For almost three decades routine 
practice has been to graft a single internal mammary artery (SIMA) to the left anterior 
descending coronary artery and to use vein or radial artery grafts to the other 
coronary arteries.(1) Better long-term patency of mammary artery grafts and 
evidence of improved 10-year survival and reductions in recurrent angina, 
myocardial infarction and repeat revascularisation suggest that patient outcomes 
could be further improved by using bilateral internal mammary arteries (BIMA).(2)  
However, concerns that BIMA is technically more challenging and may increase 
surgery-related mortality and sternal wound complications have restrained use of 
BIMA in Europe or the USA: it accounted for fewer than 5% of US cases in 2009.(3-
5) 
A meta-analysis reported a significant reduction in mortality with BIMA over 
SIMA (hazard ratio 0.79; 95% CI 0.75 to 0.84) across nine observational studies 
including 15,583 patients with mean follow-up exceeding nine years.(6) However 
evidence from randomised trials of long-term survival benefits with BIMA is still 
awaited.  The multinational Arterial Revascularisation Trial (ART) (one of the largest 
trials ever conducted in cardiac surgery) randomised 3102 CABG patients to SIMA 
(n=1554) or BIMA (n=1548) and will eventually provide valuable information on the 
impact of BIMA on 10-year survival and the need for repeat revascularisation.(7)  
ART has however already reported on the ‘safety’ of the procedure, finding similar 
clinical outcomes across trial arms at one-year post randomisation, and a small 
absolute increase (1.3%) in the need for sternal wound reconstruction with BIMA.(8) 
5 
 
As CABG is a high volume procedure (in England and Wales, for example, 
around 16,000 first time surgeries annually) it is important to consider the potential 
impact on costs as well as effectiveness of a move from SIMA to BIMA grafts. 
Therefore a health economic evaluation was designed as an integral part of ART and 
will ultimately report on the cost-effectiveness of BIMA versus SIMA at 10 years. 
Here we report an analysis of detailed health care resource use data collected in 
each trial arm out to one-year post randomisation, allowing unbiased comparison of 
the costs of SIMA and BIMA for the first time, and direct quantification of any short-
term cost increases with BIMA on account of additional surgical complexities and 
impaired wound healing. Secondary aims are to explore resource use and cost 
differences between SIMA and BIMA for clinical subgroups where surgical outcomes 
could differ, and to consider variations in resource use across different countries in 
the trial. 
The findings should be of interest to clinicians and health policy makers 
considering the potential cost implications of moving from SIMA to BIMA, and will 
also be essential inputs into the final cost-effectiveness analysis of the ART trial, 
alongside estimates of longer-term costs, repeat revascularisation, survival, and 
health related quality of life.     
 
METHODS 
Full details of the ART protocol, baseline and one year safety outcomes are 
published elsewhere.(7, 8)  ART is a multi-centre randomised controlled trial 
involving 28 hospitals across seven countries and randomised CABG patients in a 
1:1 ratio to receive SIMA or BIMA grafts. Patients were eligible for ART if they had 
multi-vessel coronary artery disease and were to undergo CABG. Patients requiring 
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single grafts or re-do CABG were excluded. The ART study complied with the 
Declaration of Helsinki. Prior ethical approval was obtained in participating centres 
and each patient was required to provide written informed consent. The Clinical 
Trials and Evaluation Unit (CTEU) at the Royal Brompton and Harefield NHS 
Foundation Trust in London provided central co-ordination, and the study was 
sponsored by the University of Oxford. 
ART was designed to detect an absolute 5% reduction in 10-year all-cause 
mortality (from 25% to 20%) with 90% power at a 5% significance level, and 
randomised 1554 patients to SIMA and 1548 patients to BIMA between 30th June 
2004 and 20th December 2007. Data on health care resource use and health-related 
quality of life (EuroQol EQ-5D and shortened World Health Organisation Rose 
Angina Questionnaire)(9, 10) are also being collected. 
 
Measurement of resource use 
During the initial inpatient admission data were collected for each patient on time in 
theatre (arrival in the anaesthetic room to final skin closure), total cardiopulmonary 
bypass time, blood products, platelets and fresh frozen plasma used, use of a cell 
saver machine for autologous blood transfusion, occurrence and duration of return to 
theatre, need for additional PRBCs, time receiving ventilation, use of an intra-aortic 
balloon pump, days receiving inotropic support or renal support therapy, and use of 
haemofiltration drugs. 
Patient level data were also collected on treatments for sternal wound 
infections (antibiotics, debridement, vacuum assisted closure (VAC) dressings, and / 
or sternal reconstruction), serious adverse events (myocardial infarction, 
cerebrovascular accident, major bleed/other vascular events, further CABG or 
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PTCA, and other), total hours in intensive care (ITU), total days in high dependency 
units (HDU), and total days on a cardiac surgery ward.   
Discharge to home, local hospital, nursing home, or elsewhere was recorded, 
as were medications prescribed.  At six weeks post randomisation information was 
collected on medication use, subsequent sternal wound infections and their 
treatment, serious adverse events, visits to a General Practitioner (GP), practice 
nurse, hospital outpatient clinic, or cardiac rehabilitation clinic, and duration of any 
hospital readmission. These same data were captured by telephone interview at 12 
months post randomisation.   
 
Measurement of Costs 
Costs were not evaluated separately for each geographical location (by centre or 
country). Instead, UK unit costs (£ 2013/14) taken from national and local sources 
were used to value all patient-level resource use data. The perspective used was 
that of the healthcare system, and out-of-pocket costs such as travel to GP surgeries 
were not collected. Hospital costs are based on standard tariffs such as NHS 
reference costs. Where individual drug usage was not available, for example for 
antibiotics after surgery, assumptions based on clinical opinion and local procedures 
at one UK hospital were used. Supplementary Table 1 and accompanying text 
provide a detailed description of sources, methods and assumptions.  
 
Statistical Analysis 
Approximately 4% of trial resource use data items were missing across the 12 
months; these were assumed to be missing at random and multiple imputation (MI) 
with chained individual linear or logistic regression equations was used to impute 
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missing values for each variable.(11) All imputation equations included age, gender, 
treatment allocation, diabetes, and smoking. Five values were imputed for each 
missing data cell and Rubin’s Rule used to summarise across the imputed 
datasets.(11)  
Continuous data were summarised using means and standard deviations and 
categorical data using percentages.  When comparing between trial arms, mean 
differences and 95% confidence intervals for differences were calculated, and two-
sample t-tests were applied.  All data analyses were performed using STATA 12 
(StataCorp, College Station, Texas). 
 
Sensitivity Analyses 
The low frequency of many events (for example inpatient SAEs and sternal wound 
reconstructions) and the low unit costs of many elements of care (for example 
inhalational anaesthetics) mean that even extreme changes to many unit costs and 
resource use assumptions would not significantly change study results. Sensitivity 
analyses were used to explore the effect of imputing missing data, and of including 
only patients who received the surgery they were allocated. 
 
Sub-group Analyses 
Resource use and costs were compared between BIMA and SIMA arms for the 
following sub-groups: diabetic vs non-diabetic, age ≥ 70 years vs <70 years, on-
pump vs off-pump, prior vs no prior MI, New York Heart Association (NYHA) Class I 
and II vs NYHA Class III and IV, and Canadian Cardiovascular Society (CCS) class 
0, I and II vs CCS class III and IV. 12-month costs were also compared across the 
9 
 
three countries each recruiting more than 100 patients to the trial (UK, Poland, 
Australia).  
 
RESULTS 
Table 1 shows the baseline characteristics for patients in each arm of the trial. The 
groups were well balanced with respect to demographic and clinical characteristics, 
and disease/symptom severity.  
 
Table 1: Baseline demographic and clinical characteristics by trial arm 
 SIMA (n=1554) BIMA (n=1548) 
Male – n (%) 
Age at randomisation– mean (SD) 
Country – n (%) 
   UK 
   Poland 
   Australia 
   India 
   Brazil 
   Italy 
  Austria 
Body mass index – mean (SD) 
Systolic blood pressure (mmHg) – mean (SD) 
Diastolic blood pressure (mmHg) – mean (SD) 
Diabetic – n (%) 
Prior myocardial infarction – n (%) 
NYHA class – n (%)* 
   I 
   II 
   III 
   IV 
CCS class – n (%) 
   No angina 
   I 
   II 
   III 
1338 (86.1) 
63.5 (9.1) 
 
1021 (65.7) 
311 (20.0) 
95 (6.1) 
48 (3.1) 
40 (2.6) 
27 (1.7) 
12 (1.0) 
28.1 (4.1)* 
131.8 (18.5)‡ 
74.8 (11.1)‡ 
363 (25.3) 
681 (43.8)‡ 
 
481 (31.0) 
747 (48.1) 
263 (16.9) 
61 (3.9) 
 
128 (8.2) 
355 (22.8) 
598 (38.5) 
351 (22.6) 
1318 (85.1) 
63.7 (8.7) 
 
1032 (66.4) 
295 (19.0) 
97 (6.2) 
40 (2.6) 
42 (2.7) 
34 (2.2) 
8 (1.0) 
28.3 (4.0)† 
131.7 (18.0)§ 
75.0 (11.0)§ 
371 (24.0) 
619 (40.0)‡ 
 
481 (31.1) 
722 (46.6) 
279 (18.0) 
66 (4.3) 
 
132 (8.5) 
348 (22.5) 
582 (37.6) 
368 (23.8) 
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   IV 
Received Surgery – n (%) 
122 (7.9) 
1546 (99.5) 
118 (7.6) 
1531 (98.9) 
*Missing for 2 patients, †Missing for 6 patients, ‡Missing for 1 patient, §Missing for 3 patients 
 
 
Sternal wound infections were infrequent but twice as many occurred in patients in 
the BIMA arm than in the SIMA arm (3.3% v 1.6% respectively). Sternal wound 
infection occurring in combination with dehiscence also affected more patients in the 
BIMA arm (1.6% v 0.6% respectively). Mortality at 30 days and 12 months was 
similar across both trial arms.  
Table 2 shows mean resource use and costs per patient for the initial inpatient 
admission by trial arm (intention to treat) for all patients. The cost of initial surgery, 
cost of initial inpatient admission (not including initial surgery), and the cost between 
discharge and 12 month follow-up are also shown in Figure 1 for each trial arm. 
Theatre duration in the BIMA arm was on average 20 minutes longer than in the 
SIMA arm (95% CI 15 to 25, p<0.002). There were no statistically significant 
differences between trial arms in time on cardiopulmonary bypass, blood product 
utilisation or use of cell saver equipment, and similar proportions of patients in both 
arms were returned to theatre.  In the immediate post-operative period, time on 
ventilation and usage of intra-aortic balloon pumps, inotropes, renal support therapy, 
and haemofiltration were similar between arms. 
The proportion of patients receiving treatments for sternal wound problems 
was small, but significantly more patients in the BIMA arm had treatment involving 
antibiotics, VAC dressings, and underwent debridement and sternal wound 
reconstruction (Table 2). The proportion of patients experiencing serious events 
during the initial inpatient episode was similar in both arms, but with a trend towards 
an increased number of subsequent revascularisations with PTCA in the BIMA arm. 
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On average patients in the BIMA arm spent an additional two hours in ITU and 
stayed a third of a day longer on cardiac surgery wards (Table 2).
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Table 2: Mean resource use and cost (UK £ 2013-14) per patient by trial arm for the initial inpatient admission 
Resource use/cost category Mean resource use (SD) or n (%) of 
patients receiving resource 
Mean difference in resource 
use  (95% CI, p-value) 
Mean cost (SD) Mean difference in costs 
(95% CI, p-value) 
 SIMA (n=1554) BIMA (n=1548) BIMA vs. SIMA SIMA (n=1554) BIMA (n=1548) BIMA vs. SIMA 
Initial Surgery 
Time in theatre (minutes) 
  Duration related theatre costs and staff 
  Duration related anaesthetic costs 
Time on bypass (minutes) 
Surgery related consumables, n (%) 
Aprotinin during surgery, n (%) 
Red blood cells transfused (ml) 
Platelets (ml)  
Fresh Frozen Plasma (ml) 
Use of cell saver, n (%) 
Aprotinin following surgery, n (%) 
Total initial surgery costs 
 
254 (72) 
- 
- 
52 (50)  
1532 (99) 
372 (24) 
67.9 (228.0)  
9.4 (73.1) 
 20.8 (120.0) 
490 (31.5) 
89 (5.7) 
- 
 
274 (74) 
- 
- 
50 (50)  
1505 (98)  
368 (24) 
66.9 (334.1) 
10.6 (68.2)  
26.4 (147.1) 
474 (30.6) 
98 (6.3) 
- 
 
20 (15, 25; 0.000) 
- 
- 
-2 (-6, 1; 0.183) 
-1.1 (-2.1, 0.1; 0.027) 
-0.1 (-3.2, 2.9; 0.921) 
-1.0 (-21.3, 19.2; 0.920) 
1.2 (-3.9, 6.2; 0.646)  
5.6 (-4.2, 15.4; 0.262) 
-0.9 (-4.2, 2.5; 0.602) 
0.6 (-1.1, 2.3; 0.471) 
 
- 
5016 (1416)  
10 (1)  
13 (12)  
454 (73)  
77 (137) 
36 (114)  
9 (69)  
3 (17)  
32 (47)  
18 (74) 
5668 (1508) 
 
- 
5414 (1473)  
10 (1)  
12 (12)  
447 (87)  
76 (136) 
35 (154)  
11 (67) 
4 (21)  
31 (47)  
20 (78) 
6062 (1618) 
 
- 
399 (297, 501; 0.000)  
0 (0, 0; 0.610) 
-1 (-2, 0; 0.135)  
-7 (-12, -1; 0.018)  
0 (-10, 9; 0.921) 
-1 (-10, 9; 0.918)  
1 (-4, 6; 0.627)  
1 (-1, 2; 0.282)  
-1 (-4, 2; 0.597)  
2 (-3, 7; 0.471) 
393 (283, 504; 0.000) 
Returned to theatre 
 Patients returning to theatre, n (%) 
 
54 (3.5) 
 
66 (4.3) 
 
0.8 (-0.6 , 2.1; 0.255) 
 
106 (762) 
 
109 (564) 
 
3 (-44, 50; 0.900) 
Immediate post-operative period 
Ventilation time (minutes) 
Intra-aortic balloon pump, n (%) 
Inotropic support (days)  
Renal support therapy (days) 
Hemofiltration, n (%) 
 
858 (3279)  
57 (3.7)  
0.7 (2.9)  
0.1 (0.9)  
207 (13.3) 
 
963 (3051)  
68 (4.4)  
0.7 (1.4)  
0.2 (2.2)  
222 (14.4) 
 
105 (-120, 330; 0.359)  
0.7 (-0.7, 2.1; 0.305)  
-0.02 (-0.2, 0.1; 0.768) 
0.1 (-0.03, 0.2; 0.126)  
1.0 (-1.4, 3.4; 0.419) 
 
519 (1984)  
21 (105)  
4 (17)  
86 (590)  
0.1 (0.4) 
 
583 (1846)  
25 (115)  
4 (10)  
148 (1501)  
0.1 (0.5) 
 
64 (-72, 200; 0.359)  
4 (-4, 12; 0.305)  
0 (-1, 1; 0.676) 
63 (-18, 143; 0.126)  
0 (0, 0; 0.335) 
In-hospital sternal wound problems*, n (%) 
 Treatment including antibiotics, 
 Treatment including debridement, 
 Treatment including vac dressing, 
 Treatment including reconstruction, 
Total cost of sternal wound problems 
 
8 (0.5) 
2 (0.1) 
2 (0.1) 
2 (0.1) 
- 
 
22 (1.4) 
11 (0.7) 
9 (0.6) 
13 (0.8) 
- 
 
0.9 (0.2,1.6; 0.010) 
0.6 (0.1, 1.0; 0.012) 
0.5 (0.1, 0.9; 0.034) 
0.7 (0.2, 1.2; 0.004) 
- 
 
0 (5) 
3 (86) 
0 (10) 
6 (171) 
10 (266) 
 
1 (16) 
22 (309) 
2 (30) 
40 (434) 
65 (714) 
 
1 (0, 2; 0.002) 
19 (3, 34; 0.023) 
2 (0, 3; 0.038) 
34 (11, 57; 0.004) 
55 (17, 93; 0.004) 
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In-hospital SAE treatment, n (%) 
  Myocardial Infarction 
  Cerebrovascular accident 
  Further CABG 
  Further PTCA 
  Revascularisation with catheter 
  Major bleed 
 
25 (1.6) 
17 (1.1) 
2 (0.1) 
1 (0.1) 
3 (0.2) 
36 (2.3) 
 
26 (1.7) 
15 (1.0) 
5 (0.3) 
8 (0.5) 
1 (0.1) 
42 (2.7) 
 
0.1 (-0.8, 1.0; 0.877) 
-0.1 (-0.8, 0.6; 0.731) 
0.2 (-0.1, 0.5, 0.254) 
0.5 (0.1, 0.8; 0.019) 
-0.1 (-0.4, 0.1; 0.319) 
0.4 (-0.7, 1.5; 0.481) 
 
15 (116) 
12 (114) 
6 (177) 
1 (59) 
3 (72) 
132 (877) 
 
15 (119) 
11 (118) 
16 (280) 
15 (229) 
1 (42) 
169 (1052) 
 
1 (-8, 9; 0.877) 
-1 (-9, 7; 0.874) 
10 (-7, 26; 0.254) 
14 (2, 26; 0.020) 
-2 (-6, 2; 0.319) 
36 (-32, 105; 0.296) 
In-hospital stay 
 Time in ITU (hours)  
 Time in HDU (days)  
 Time on general cardiac wards (days) 
 
35.3 (102.7)  
1.2 (3.0)  
6.9 (5.6) 
 
37.7 (90.6)  
1.3 (3.2)  
7.2 (6.5) 
 
2.4 (-4.5, 9.2; 0.497)  
0.1 (-0.2, 0.3; 0.732)  
0.3 (-0.2, 0.7; 0.201) 
 
946 (2751)  
450 (1121)  
1831 (1481) 
 
1009 (2428)  
464 (1186)  
1905 (1721) 
 
63 (-119, 246; 0.497)  
14 (-67, 95; 0.732)  
74 (-39, 187; 0.201) 
Total cost, initial inpatient admission - - - 9811 (6390) 10601 (6601) 791 (333, 1248; 0.001) 
* Categories are not mutually exclusive (for example a patient receiving antibiotics and a vac dressing would appear under both headings).
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The total cost of the initial inpatient admission was £10,601 (£6,601) in the 
BIMA arm and £9,811 (£6,390) in the SIMA arm, giving a mean cost increase of 
£791 per patient (95% CI £333 to £1,248, p<0.001).  Results were similar after 
adjustment for age, sex and diabetes: BIMA was associated with a cost increase of 
£778 (95% CI £323 to £1233, p=0.001) over the initial inpatient admission. Longer 
time in theatre and on various hospital wards by patients in the BIMA arm accounted 
for approximately two thirds of additional costs incurred.  Treatments for additional 
sternal wound problems accounted for a further 7%, and renal support therapy and 
longer ventilation time for a further 8% each.   
Table 3 shows mean resource use and cost per patient in each trial arm from 
initial hospital discharge to 12 months follow-up.  Similar proportions of patients in 
each arm were transferred to local hospitals, nursing homes and other institutions.  
At six weeks the overall number of patients requiring treatment for sternal wound 
problems was small but more patients in the BIMA arm received antibiotics and 
debridement.  
The two trial arms were comparable in terms of GP and nurse visits, cardiac 
rehabilitation visits and hospital readmissions to 12 months, but patients in the BIMA 
arm had on average 0.5 more (95% CI 0.1 to 0.9, p=0.015) hospital outpatient clinic 
visits than patients in the SIMA arm. There were no differences between trial arms in 
the proportion of participants experiencing serious adverse events, or the cost of 
these, between discharge and 12 months.  
The total cost of the follow-up period from hospital discharge was £3,238 
(£7,118) in the BIMA arm and £2,906 (£6,203) in the SIMA arm (mean cost 
difference £332, 95% CI -£141 to £805, p=0.169).  The mean overall total cost per 
patient out to 12 months from randomisation was £13,839 (£10,534) in the BIMA arm 
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and £12,717 (£9,717) in the SIMA arm (mean cost difference £1122, 95% CI £407 to 
£1,838, p=0.002) (Figure 1).  
Figure 1: Mean (95% CI) per-patient cost by trial arm at various follow-up time 
points 
(*see separate file)
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Table 3:  Mean resource use and cost (UK £ 2013-14) per patient by trial arm from hospital discharge to 12-month follow-
up 
 
e Mean resource use (SD) or n (%) of 
patients receiving resource 
Mean difference in resource 
use  (95% CI, p-value) 
Mean cost (SD) Mean difference in costs 
(95% CI, p-value) 
 SIMA (n=1554) BIMA (n=1548) BIMA vs. SIMA SIMA (n=1554) BIMA (n=1548) BIMA vs. SIMA 
At hospital discharge, n (%) 
  Home 
  Transferred to local hospital 
  Transferred to nursing home 
  Transferred to other institution  
Referral for cardiac rehabilitation 
 
1320 (85.0) 
157 (10.1) 
6 (0.4) 
56 (3.6) 
1208 (77.7) 
 
1311 (84.7) 
158 (10.2) 
5 (0.3) 
56 (3.6) 
1228 (79.3) 
 
-0.2 (-2.8, 2.3; 0.853) 
0.1 (-2.0, 2.2; 0.915) 
-0.1 (-0.5, 0.4; 0.768) 
-0.0 (-1.3, 1.3; 0.986) 
1.6 (-1.3, 4.5; 0.273) 
 
- 
189 (563) 
221 (3558) 
101 (524) 
- 
 
- 
198 (588) 
185 (3255) 
101 (523) 
- 
 
- 
10 (-31, 50; 0.644) 
-36 (-276, 204; 0.768) 
0 (-37, 37; 0.986) 
- 
Sternal wound problems to 6 weeks*, n (%) 
Treatment with antibiotics 
 Treatment with debridement 
 Treatment with vac dressing 
 Treatment with reconstruction 
Total cost of  sternal wound problems 
 
16 (1.0) 
10 (0.6) 
10 (0.6) 
4 (0.3) 
- 
 
30 (1.9) 
22 (1.4) 
17 (1.1) 
11 (0.7) 
- 
 
0.9 (0.1, 1.7; 0.036) 
0.8 (0.1, 1.5; 0.032) 
0.4 (-0.2, 1.1; 0.173) 
0.4 (-0.1, 0.9; 0.069) 
- 
 
1 (12) 
15 (191) 
2 (23) 
12 (241) 
103 (1045) 
 
2 (14) 
35 (301) 
3 (30) 
34 (400) 
246 (1976) 
 
0 (0, 1; 0.294) 
20 (2, 38; 0.026) 
1 (-1, 3; 0.173) 
22 (-2, 45; 0.069) 
143 (32, 254; 0.012) 
Mean number of medications (SD) 3.3 (1.1) 3.3 (1.1) 0.0 (-0.1, 0.1; 0.960) 56 (73) 59 (73) 3 (-3, 8; 0.372) 
Health care contacts discharge to 12 months 
  GP visits 
  Nurse visits 
  Outpatient clinic visits 
  Cardiac rehabilitation visits 
  Hospital admissions 
  Number of nights in hospital 
 
6.5 (5.0) 
3.1 (8.2) 
1.9 (2.2) 
5.1 (8.9) 
0.3 (0.8) 
2.6 (8.9) 
 
6.3 (5.2) 
3.4 (8.2) 
2.4 (7.5) 
5.2 (8.7) 
0.3 (0.8) 
3.1 (11.5) 
 
-0.2 (-0.5, 0.2; 0.328) 
0.3 (-0.3, 0.8; 0.357) 
0.5 (0.1, 0.9; 0.015) 
0.1 (-0.5, 0.7; 0.717) 
0.0 (-0.1, 0.1; 0.594) 
0.5 (-0.3, 1.2; 0.208) 
 
298 (231) 
43 (112) 
252 (293) 
383 (541) 
- 
685 (2356) 
 
290 (240) 
47 (112) 
316 (987) 
391 (532) 
- 
812 (3038) 
 
-8 (-25, 8; 0.328) 
4 (-4, 12; 0.357) 
64 (13,115; 0.015) 
8 (-30, 47; 0.667) 
- 
127 (-71, 325; 0.208) 
SAE treatment from discharge to 12 months, n (%) 
  Myocardial Infarction   
  Cerebrovascular accident  
  Further CABG 
  Further PTCA  
  Revascularisation with catheter 
 
10 (0.6) 
13 (0.8) 
- 
22 (1.4) 
3 (0.2) 
 
9 (0.6) 
8 (0.5) 
1 (0.1) 
19 (1.2) 
8 (0.5) 
 
-0.1 (-0.6, 0.5; 0.825) 
-0.3 (-0.9, 0.3; 0.278) 
0.1 (-0.1, 0.2; 0.316) 
-0.2 (-1.0, 0.6; 0.646) 
0.3 (-0.1, 0.7; 0.129) 
 
13 (171) 
22 (267) 
- 
53 (463) 
4 (97) 
 
11 (152) 
12 (190) 
5 (206) 
41 (392) 
15 (223) 
 
-3 (-14, 9; 0.665) 
-11 (-27, 6; 0.200) 
5 (-5, 15; 0.316) 
-11 (-41, 19; 0.469) 
11 (-1, 24; 0.063) 
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  Major bleed 
  Other AEs (cost of hospital stay only) 
  Death (cost of hospital stay only) 
5 (0.3) 
276 (17.8) 
21 (1.3) 
6 (0.4) 
254 (16.4) 
20 (1.3) 
0.1 (-0.3, 0.5; 0.758) 
-1.3 (-4.0, 1.3; 0.317) 
-0.1 (-0.9, 0.7; 0.885) 
27 (487) 
405 (2219) 
51 (999) 
36 (643) 
450 (2752) 
23 (647) 
8 (-32, 48; 0.686) 
45 (-131, 221; 0.614) 
-28 (-87, 31; 0.357) 
Total costs from discharge to 12 months - - - 2906 (6203) 3238 (7118) 332 (-141, 805; 0.169) 
Total overall costs at 12 months - - - 12717 (9719) 13839 (10534) 1122 (407, 1838; 0.002) 
*categories are not mutually exclusive (for example a patient receiving antibiotics and a vac dressing would appear under both headings) 
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Results were similar after adjustment for age, sex and diabetes: BIMA was 
associated with £1081 (95% CI £376 to £1787, p=0.003) higher costs per patient out 
to 12 months from randomisation. 
 
Sensitivity Analysis 
1494 of the 1554 patients allocated to SIMA and 1294 of the 1548 patients allocated 
to BIMA received the allocated procedure. Supplementary Table 2 reports a “per 
protocol” analysis comparing costs by trial arm: as in the base case analysis, total 
inpatient costs were significantly greater for those receiving BIMA than for SIMA, and 
total costs at 12 months were significantly greater for BIMA than for SIMA (£1,243 
more costly for BIMA, with 95% CI £501 to £1,985, p<0.001).  
Supplementary Table 3 reports total costs by trial arm when no multiple 
imputation was performed and calculations were based on “complete cases” only. As 
in the base case analysis, the total cost of the initial hospital stay was significantly 
greater for BIMA than for SIMA, driven by time in theatre and ward stays, and there 
was a non-significant trend towards BIMA being more costly than SIMA at 12 month 
follow-up. 
 
Sub-group Analyses 
Table 4 shows total costs to 12 months for the various sub-group analyses and 
country comparisons; Supplementary Tables 4-10 provide full details. Tests showed 
no evidence of interaction between subgroup and treatment allocation, although 
additional costs with BIMA for diabetic patients were more than twice those of non-
diabetic patients (£2,119 v £803 per patient respectively), for on-pump patients were 
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more than twice those for off-pump patients (£1,575 v £623 per patient respectively), 
and also were higher for patients with more severe angina and cardiac disease.  
Table 4: Total costs to 12-months follow-up by trial arm and by various subgroups 
Subgroup Mean total cost (SD) Mean difference in total cost 
(95% CI, p-value)* 
 SIMA BIMA BIMA vs. SIMA 
No history of diabetes (n=2368) 
Insulin/non-insulin dependent diabetes (n=734) 
12555 (9617) 
13249 (10042) 
13557 (9788) 
15369 (12504) 
803 (18 , 1587 ; 0.045) 
2119 (473 , 3766 ; 0.012) 
Age <70 (n=2271) 
Age > 70 (n=831) 
11791 (7439) 
15175 (13800) 
13005 (8512) 
16186 (14568) 
1214 (554 , 1873 ; 0.000) 
1011 (-925 , 2976 ; 0.306) 
Off-pump (n=1259) 
On pump (n=1819) 
12826 (12201) 
12732 (7628) 
13449 (10958) 
14307 (10202) 
623 (-660 , 1906 ; 0.341) 
1575 (745 , 2404 ; 0) 
No prior MI (n=1800) 
Prior MI (n=1300) 
12617 (9931) 
12850 (9452) 
13418 (10256) 
14449 (10911) 
801 (-137 , 1740 ; 0.094) 
1599 (490 , 2708 ; 0.005) 
NYHA class I & II (n=2431) 
NYHA class III & IV (n=669) 
12774 (9968) 
12513 (8751) 
13690 (9769) 
14361 (12852) 
916 (128 , 1703 ; 0.023) 
1849 (166 , 3532 ; 0.031) 
CCS class 0 , I , II (n=2143) 
CCS class III, IVa/b/c (n=959) 
12796 (10250) 
12537 (8387) 
13633 (10047) 
14291 (11525) 
837 (-27 , 1701 ; 0.058) 
1754 (470 , 3038 ; 0.007) 
UK (n=2053) 
Poland (n=606) 
Australia (n=192) 
12985 (11334) 
11489 (4443) 
14744 (6265) 
13838 (10817) 
12319 (5519) 
16066 (8709) 
853 (-107 , 1812 ; 0.082) 
830 (9 , 1650 ; 0.048) 
1322 (-843 , 3486 ; 0.23) 
* No tests for interaction between subgroup and treatment allocation were statistically 
significant 
 
 
DISCUSSION 
This analysis was an integral part of the ART Trial, the largest randomised 
comparison of bypass grafting using single (SIMA) or bilateral (BIMA) mammary 
arteries. Our comprehensive results show that around 70% of the additional costs 
observed in the BIMA arm at 12 months (£791, 95% CI £333 to £1,248, p=0.001) 
were incurred during the initial inpatient episode, mainly due to longer time in theatre 
and on hospital wards. Treatment costs associated with a small increase in sternal 
wound problems were significant but not sizeable. Other inpatient resource use and 
clinical events were similar across both trial arms.   
Post-hospital discharge, and with the exception of the costs of sternal wound 
problems at six weeks, there were few differences between the two trial arms to 12 
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months. The absence of manifestations of surgery-related complications requiring 
treatment in the BIMA arm over this period is reassuring. Any signs of the 
hypothesised benefits of BIMA - sustained graft patency leading to a reduction in 
repeat revascularisation, lower use of anti-anginal medication, and improved survival 
- are only likely to become evident in the longer term.  Previous trial-based studies of 
the cost-effectiveness of CABG versus percutaneous transluminal coronary 
angioplasty (PTCA) have consistently found that differences in costs arising from 
repeat revascularisation and medication use take time to emerge; in the SYNTAX 
trial these emerged over 5 years and increased when simulated over a lifetime;(12) 
in BARI differences did not emerge until after 12 months and persisted for at least 7 
years.(13) Differences between BIMA and SIMA may take even longer to appear due 
to the good long-term graft patency already achievable with SIMA, and a full analysis 
of costs, outcomes and cost-effectiveness is planned at the primary ART endpoint of 
10 years. 
Exploratory sub-group analyses suggested that the incremental costs of BIMA 
over SIMA at 12-months could be around £1300 higher for diabetic patients as 
compared with non-diabetic patients, incurred mainly following hospital discharge. 
However, there was no evidence of interaction between subgroup and treatment 
allocation.   
Diabetes and BIMA have been reported as independent risk factors for deep 
sternal wound infection following CABG in a number of observational studies 
performing multivariate analyses.(14, 15) However a recent study including 
1,526,360 CABG patients treated in the US reported that whilst diabetes mellitus 
was an independent predictor of deep sternal wound infection, BIMA was not, and 
was only associated with an increased risk of DSWI in patients with chronic 
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complications of diabetes mellitus.(16) We found that, during the initial inpatient 
admission, the higher mean cost per patient of treatment for sternal wound problems 
in the BIMA arm compared to SIMA was more pronounced amongst diabetic than 
non-diabetic patients, although the absolute costs involved were relatively small. 
This pattern was even stronger for sternal wound problems occurring between 
discharge and 6 weeks (Supplementary Table 4).  
We found some evidence that the BIMA versus SIMA difference in cost was 
greater for on-pump patients: a £1,575 excess compared to £623 for off-pump 
patients. This appears to be driven by the BIMA group: within the SIMA group, off-
pump and on-pump patients appeared to have very similar costs, although the non-
randomised comparison could be confounded, and there was no evidence of 
interaction between subgroups and treatment allocation.   
The main advantage of our study is the randomised comparison, which 
greatly reduces the risk of unobserved bias. The retrospective database analysis by 
Itagaki and colleagues had a very large sample size, but it is impossible to be sure 
that reported differences between SIMA and BIMA were not confounded by other 
variables; thus, they report a shorter length of stay for BIMA versus SIMA (9.0 versus 
8.0 days) and lower costs ($85,246 versus $92,698), both in the opposite direction to 
our findings.(16)  
  Limitations of our study include the fact that we have applied UK-based unit 
costs to resource use information from all 7 countries in the study, rather than 
applying local costs by centre and country and then applying an estimation model. 
Differences in patterns of care between countries may reflect different relative prices: 
for example cost differences between BIMA and SIMA related to the initial inpatient 
admission were highly significant for Poland but not significant for UK and Australia 
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(all with BIMA more costly), while initial surgery costs were lower for BIMA in 
Australia but significantly higher for BIMA in UK and Poland, and costs of healthcare 
contacts (GP etc.) were lower for BIMA than SIMA in Australia but higher in UK and 
Poland. However, these differences were mainly not statistically significant, total cost 
differences between BIMA and SIMA at 12 months were in the same direction for all 
countries, and there was no evidence of interaction between subgroups and 
treatment allocation.  
 
CONCLUSIONS 
At 12 months from randomisation, mean costs were higher in BIMA than SIMA 
patients, primarily due to longer time in theatre and in-hospital stay, and slightly 
higher costs related to sternal wound problems. Follow-up to the primary trial 
endpoint of 10 years is continuing, and will reveal whether longer-term differences 
emerge in graft patency or in overall survival.   
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